secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2022-11-18T23:59:59+00:00
Accession:  0001125345-22-000108
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics earns $60M milestone from Provention on FDA approval of teplizumab
------------------------------------------------------------------------------

- FDA approved teplizumab BLA for type 1 diabetes; MacroGenics receives $60M milestone from Provention.
- Total potential regulatory milestones from Provention up to $170M; additional $225M in sales milestones.
- Single-digit royalty on net sales of teplizumab payable to MacroGenics.
- Cash runway extended into late 2024 based on existing cash and anticipated partner payments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534522000108/0001125345-22-000108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534522000108/mgnx-20221117.htm
  HTML page:      https://secwatch.observer/filing/0001125345-22-000108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer